ClinicalTrials.gg
Enrolling by invitationNCT07757984Updated Nov 19, 2026

Regional Nerve Block for Upper Extremity Surgery in Patients With Sarcopenia

An observational study in Sarcopenia and Nerve Block, sponsored by Chang Gung Memorial Hospital. Enrolling by invitation at 1 site in Taiwan. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Chang Gung Memorial Hospital · Observational

How we know

Updated Nov 19, 2026Now Enrolling by invitationGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 14 studies in Sarcopenia by Chang Gung Memorial Hospital — 8 open to participants now, 8 under way, none of them phase 3. Sarcopenia · Chang Gung Memorial Hospital.

Started
2026
with 1 other
Observational
3 of 14
1 open now
Registered
13th of 14
by date

Among the 14 studies in Sarcopenia by Chang Gung Memorial Hospital, this one is one of 2 that started in 2026, is one of 3 observational ones, and was the 13th registered.

Sarcopenia

1,333 studies on the registry are indexed under Sarcopenia; 419 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

8 of the 14 studies in Sarcopenia by Chang Gung Memorial Hospital are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 247 Sarcopenia studies recruiting now, 154 (62%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 50 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Sarcopenia by Chang Gung Memorial Hospital, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about the impact of sarcopenia (muscle loss) on the efficacy of regional nerve blocks and postoperative recovery in patients undergoing upper extremity surgery. The main questions it aims to answer are:

  1. Does sarcopenia affect the onset time and success rate of peripheral nerve blocks?
  2. How does sarcopenia influence postoperative pain control and opioid consumption compared to patients receiving pure general anesthesia?

Participants will undergo a preoperative muscle assessment, which includes a chair stand test and a brief ultrasound of the thigh muscle. Researchers will then observe and record their nerve block onset time (if applicable), postoperative pain scores, and recovery metrics during their hospital stay up to postoperative day 2.

03

Conditions studied

  • Sarcopenia
  • Nerve Block

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study population comprises patients aged 50 years and older with an American Society of Anesthesiologists (ASA) physical status of I to III, who are scheduled to undergo upper extremity surgery under general anesthesia. Eligible participants must be capable of cooperating with postoperative pain and functional assessments.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age>=50 years old
  • Receiving upper limb surgery under general anesthesia

Exclusion criteria

Exclusion Criteria:

  • Severe cognitive impairment or inability to cooperate with pain and motor assessment
  • Pre-existing neuropathy of the musculocutaneous, median, radial or ulnar nerve
  • (for nerve block group) to regional nerve blockade
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • General anesthesia alone

    Other: sarcopenia · Other: Non-sarcopenia · Procedure: General Anesthesia

  • General anesthesia combine infraclavicular brachial plexus block, with sarcopenia

    Other: sarcopenia · Procedure: General Anesthesia · Procedure: Nerve Block

  • General anesthesia combine infraclavicular brachial plexus block, without sarcopenia

    Other: Non-sarcopenia · Procedure: General Anesthesia · Procedure: Nerve Block

Interventions

  • Othersarcopenia

    Patients identified with sarcopenia based on preoperative muscle assessment.

  • OtherNon-sarcopenia

    Patients with normal muscle mass based on preoperative muscle assessment.

  • ProcedureGeneral Anesthesia

    received general anesthesia alone

  • ProcedureNerve Block

    general anesthesia combined with nerve block

06

What researchers measure

Primary outcomes

  1. time to first rescue analgesia

    Time frame: From the completion of surgery up to Postoperative Day 2

Secondary outcomes

  1. Nerve block onset

    Time frame: From the completion of local anesthetic injection up to 30 minutes

  2. Nerve block duration

    Time frame: From the successful onset of sensory block to the patient's first report of pain at the surgical site, assessed up to postoperatively day 2

  3. Intraoperative Mean Arterial Pressure (MAP) and Heart Rate (HR)

    Mean Arterial Pressure (MAP) measured in mmHg and Heart Rate (HR) measured in beats per minute, assessed continuously using standard non-invasive or invasive hemodynamic monitors.

    Time frame: During surgery (From the induction of anesthesia to the end of surgery, an average of 2 hours)

  4. Postoperative NRSFrom the end of surgery up to 48 hours postoperatively.

    Time frame: From the end of surgery up to postoperative day 2

  5. Total opioid consumption

    Time frame: From the end of surgery up to postoperative day 2

  6. Incidence of Local Anesthetic Systemic Toxicity (LAST)

    LAST is defined as the occurrence of adverse central nervous system signs (e.g., altered mental status, seizures, tinnitus) or cardiovascular signs (e.g., arrhythmias, profound hypotension, cardiac arrest) following the administration of local anesthetics. It will be assessed clinically by the attending anesthesiologist and recorded as a binary outcome (Yes/No).

    Time frame: From the initiation of nerve block up to 24 hours postoperatively

  7. Incidence of postoperative delirium

    The incidence of postoperative delirium will be assessed using the Confusion Assessment Method (CAM). The CAM diagnostic algorithm evaluates four features: (1) acute onset and fluctuating course, (2) inattention, (3) disorganized thinking, and (4) altered level of consciousness. Delirium is considered present if features 1 and 2 are observed, along with either feature 3 or 4. The outcome will be recorded as a binary variable (Yes/No).

    Time frame: From the end of surgery up to postoperative day 2

  8. ICU stay

    Time frame: From ICU admission up to postoperative day 2

07

Study locations

1 site
  • ChangGung Memorial Hospital
    Taoyuan, Taiwan
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Aug 2028, 23 months after the start.

Of 191 non-industry observational studies under Sarcopenia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 63. This study's planned 23 months is below that.

Counting every sponsor, half of 193 studies reached it within 26 months; a quarter within 12 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2026
First posted
Aug 11, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Aug 31, 2028
CompletionEst.
Aug 31, 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Nov 19, 2026
Contact
No study contact listed any more: removed c•••@gmail.com · •••3825
Nov 19, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • ChangGung Memorial Hospital · Taoyuan, TaiwanContact removed c•••@gmail.com · •••3825
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Not yet recruiting→Enrolling by invitation
    Contact No study contact listed any more: removed c•••@gmail.com · •••3825
    Site contacts Changed at 1 site. See the sites
    Show the site
    • ChangGung Memorial Hospital · Taoyuan, TaiwanContact removed c•••@gmail.com · •••3825
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07757984
Responsible party
Sponsor
First posted
Aug 11, 2026
Start date
Sep 1, 2026
Primary completion
Aug 31, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Tsai
principal investigator · Chang Gung Memorial Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion